Development of the artificial bone using phosphorylated pullulan in experimental cleft palate model
Project/Area Number |
24792271
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Orthodontic/Pediatric dentistry
|
Research Institution | Tohoku University |
Principal Investigator |
SEIRYU Masahiro 東北大学, 歯学研究科(研究院), 助教 (80510023)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
Keywords | 歯学 / 再生医学 / 細胞・組織 |
Outline of Final Research Achievements |
The purpose of this study is as follows, 1) To evaluate the period of bone healing in extracted sockets of first molars in rats using tricalcium phosphate and phosphorylated pullulan. 2) To create a cleft palate model of rat and beagle. 3) To evaluate the period of bone healing in the cleft palate model of rat and beagle using tricalcium phosphate and phosphorylated pullulan. The result of this study is as follows, 1) The CT value of the group of tricalcium phosphate and phosphorylated pullulan was higher than other groups. 2) The most suitable mixture ratio of the tricalcium phosphate and phosphorylated pullulan was able to determine. 3) The cleft palate model of rat and beagle were succeeded without any trouble.
|
Report
(4 results)
Research Products
(14 results)
-
-
-
[Journal Article] Compressive force-produced CCN2 induces osteocyte apoptosis through ERK1/2 pathway2014
Author(s)
K Hoshi, H Kawaki, I Takahashi, N Takeshita, M Seiryu, S A Murshid, T Masuda, T Anada, R Kato, H Kitaura, O Suzuki, T Takano-Yamamoto
-
Journal Title
J Bone Miner Res
Volume: 29
Issue: 5
Pages: 1244-1257
DOI
NAID
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-